The #1 Commonly Missed Early Sign of Lung Cancer, According to Oncologists
“Lung cancer is the leading cause of cancer death in the U.S. after skin cancer, according to the American Cancer Society (ACS). The disease is to blame for about 1 in 5 cancer deaths, and the ACS estimates more than 127,000 people will die from it this year.”
Outcomes of Lung Cancer Screening Using LDCT Imaging for Over 1 Million Individuals
“In 2013, low-dose CT (LDCT) imaging was recommended for lung cancer screening (LCS), making approximately 8 million Americans eligible.”
Breakthrough Targeted Therapy Approach for Non-Small Cell Lung Cancer Helps Patients With a Genetic Mutation Live Longer
“The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy. But patients with an epidermal growth factor receptor (EGFR) gene mutation have not seen the same survival benefit.”
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
“SAN DIEGO, Sept. 9, 2023 /PRNewswire/ — Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.”
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
“– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studied –“
Promising Results in TROPION-Lung04 Trial for Advanced Lung Cancer
“Initial results from the TROPION-Lung04 Phase Ib trial showed that datopotamab deruxtecan (Dato-DXd) in combination with Imfinzi (durvalumab), an anti-PD-L1 therapy, with or without carboplatin demonstrated encouraging responses and no new safety signals in patients with previously untreated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.”
AI more accurately identifies patients with advanced lung cancer that respond to immunotherapy and helps doctors select treatments
“Newswise — Treatment planning for lung cancer can often be complex due to variations in assessing immune biomarkers. In a new study, Yale Cancer Center researchers at Yale School of Medicine used artificial intelligence (AI) tools and digital pathology to improve the accuracy of this process.”
Lung Cancer Screening: Making it Meaningful for Nonsmoking Asian Women
“”If you build it, they will come,” is the hallmark line from the 1989 baseball movie “Field of Dreams.” Unfortunately, that hasn’t necessarily proven true in low-dose CT lung cancer screening (LCS). Hitting a home run with widespread programming has been a challenge in the U.S., and despite health insurance coverage for lung cancer screening in the United States since 2015, “fewer than 10% of eligible persons” participate in LCS, noted international researchers.”
NHS England invites more than one million people for lung cancer checks
“More than one million people (1,052,083) have been invited for a lung cancer check, as part of the biggest programme to improve early lung cancer diagnosis in health service history.”
Rybrevant Betters Outcomes in Certain Lung Cancer Populations
“Rybrevant (amivantamab-vmjw) improved progression-free survival when given with or without lazertinib to patients with locally advanced or metastatic EGFR exon 19 (ex19del) or L8588R substitution non-small cell lung cancer that has previously progressed on Tagrisso (Osimertinib), according to findings from the phase 3 MARIPOSA-2 study announced in a press release by Janssen.”
